Management ChangeJul 13, 2026, 04:16 PM
MBX Biosciences Appoints Steve Hoerter as CEO, John Smither as CFO
AI Summary
MBX Biosciences announced significant leadership changes, appointing Steve Hoerter as its new Chairman and Chief Executive Officer, succeeding co-founder Kent Hawryluk. John Smither, previously Interim CFO, has been named Chief Financial Officer. These changes are effective immediately. The company also reaffirmed its commitment to key milestones in the second half of 2026, including initiating a Phase 3 trial for canvuparatide and releasing data for MBX 4291.
Key Highlights
- Steve Hoerter appointed Chairman and Chief Executive Officer, effective immediately.
- Kent Hawryluk steps down as President, CEO, and a member of the Board of Directors.
- John Smither appointed Chief Financial Officer, effective immediately.
- Mr. Hoerter was Executive Chairman since November 2025 and previously CEO of Deciphera Pharmaceuticals.
- Mr. Smither served as Interim CFO since March 2026 and was previously CFO of Arcutis Biotherapeutics.
- Company remains on track to initiate Phase 3 trial of canvuparatide in H2 2026.
- Company expects to nominate a GLP-1/GIP/GCGR triple agonist candidate for obesity in H2 2026.
- Anticipates 12-week multiple ascending dose data from MBX 4291 in the second half of 2026.
Price Impact
More from MBX